DOCSLIB.ORG

Measure Name: Cervical Cancer Screen

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Measure Name: Cervical Cancer Screen Measure Name: Cervical Cancer Screen Owner: NCQA (CCS) Measure Code: CER Lab Data: Y Rule Description: The percentage of women 21-64 years of age who received one or more Pap tests to screen for cervical cancer. Applicable Provider Specialty: Family Practice, Internal Medicine, Mixed Specialties Clinic, Obstetrics-Gynecology General Criteria Summary 1. Continuous enrollment: 3 year 2. Anchor date: 31st December of the measurement year 3. Gaps in enrollment: One 45-day gap allowed in each year of continuous enrollment 4. Medical coverage: Yes 5. Drug coverage: No 6. Attribution time frame:2 year 7. Exclusions apply: Yes, when numerator is negative 8. Age range: 21-64 years Summary of changes for 2011 Added CPT codes 57540, 57545, 57550, 57555, 57556, and 58548 to Table CCS-B: Codes to Identify Exclusions ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ Denominator Description: All women aged 24-64 years at the end of the measurement year Inclusion Criteria: Women who meet the age requirement in the measurement year and continuous enrollment criteria as summarized above for the coverage required. There are no claims criteria for the denominator population. Eligibility Criteria Condition # Detailed Criteria Timeframe Description Evnt Gender Code Gender Code = F AND Age is 24-64 Age in Years = 24-64 As of the end of the measurement year AND Has medical coverage Coverage Indicator Medical = Y During measurement year and the two years prior to the measurement year 12/5/2012 Page 1 Exclusion Criteria: Women with a previous hysterectomy and no residual cervix Condition # Detailed Criteria Timeframe Description Evnt Previous hysterectomy 1 Any Diagnosis Code Anytime prior to or during the with no residual cervix Table CCS-B: Codes to Identify Exclusions measurement year Or CPT Procedure Code Table CCS-B: Codes to Identify Exclusions Or ICD9 Procedure Code Table CCS-B: Codes to Identify Exclusions Exclusion Note: The exclusions are applied according to the general NCQA rule of considering exclusions only if the numerator is negative ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ Numerator Description: For each woman who meets the denominator criteria, those who received a Pap test during the measurement year or the two years prior to the measurement year Inclusion Criteria: Women who had at least one Pap test during the measurement year or the two years prior to the measurement year Condition # Detailed Criteria Timeframe Description Evnt At least one Pap test 1 Any Diagnosis Code During the measurement year or the performed Table CCS-A: Codes to Identify Cervical cancer two years prior to the measurement Screening year Or CPT Procedure Code Table CCS-A: Codes to Identify Cervical cancer Screening Or HCPCS Procedure Code Table CCS-A: Codes to Identify Cervical cancer Screening Or ICD9 Procedure Code 12/5/2012 Page 2 Table CCS-A: Codes to Identify Cervical cancer Screening Or During the measurement year or the two years prior to the measurement Revenue Code UB = 0923 year Table CCS-A: Codes to Identify Cervical cancer Screening Or LOINC = Table CCS-A: Codes to Identify Cervical cancer Screening Notes: 1. Because HCSC has historical data, the search for exclusion criteria extend to 10 years of data. 12/5/2012 Page 3 Appendix Table CCS-A: Codes to Identify Cervical Cancer Screening CPT Procedure Code Description: Pap test 88141 Cytopathology, cervical or vaginal, interpretation by physician 88142 Cytopathology, cervical or vaginal, manual screening under physician supervision 88143 Cytopathology, cervical or vaginal, manual screening and rescreening under physician supervision 88147 Cytopathology smears, cervical or vagina, screening by automated system under physician supervision 88148 Cytopathology smears, cervical or vagina, screening by automated system with manual rescreening under physician supervision 88150 Cytopathology, slides, cervical or vaginal, manual screening, under physician supervision 88152 Cytopathology, slides, cervical or vaginal, manual screening and computer assisted rescreening, under physician supervision 88153 Cytopathology, slides, cervical or vaginal, manual screening and rescreening under physician supervision 88154 Cytopathology, slides, cervical or vaginal manual screening, computer assisted rescreening, under physician supervision 88155 Cytopathology, slides, cervical or vaginal, definitive hormonal evaluation 88164 Cytopathology, slides, cervical or vaginal, manual screening, under physician supervision 88165 Cytopathology, slides, cervical or vaginal, manual screening and rescreening, under physician supervision 88166 Cytopathology, slides, cervical or vaginal, manual screening and computer assisted rescreening, under physician supervision 88167 Cytopathology, slides, cervical or vaginal, manual screening and computer assisted rescreening using cell selection, under physician supervision 88174 Cytopathology, cervical or vaginal collected in preservation fluid, automated thin layer preparation, screening by automated system, under physician supervision 12/5/2012 Page 4 88175 Cytopathology, cervical or vaginal collected in preservation fluid, screening by automated system, and manual rescreening, under physician supervision HCPCS Description: Pap test G0123 Screening Cytopathology, cervical or vaginal, automated thin layer preparation, screening by cytotechnologist under physician supervision G0124 Screening Cytopathology, cervical or vaginal, automated thin layer preparation, requiring physician interpretation G0141 Screening Cytopathology, cervical or vaginal, automated thin layer preparation, with manual rescreening, requiring physician interpretation G0143 Screening Cytopathology, cervical or vaginal, automated thin layer preparation, with manual screening and rescreening by cytotechnologist, under physician supervision G0144 Screening Cytopathology, cervical or vaginal, automated thin layer preparation, with screening by automated system, under physician supervision G0145 Screening Cytopathology, cervical or vaginal, automated thin layer preparation, with screening by automated system with manual rescreening under physician supervision G0147 Screening Cytopathology smears, cervical or vaginal, performed by automated system under physician supervision G0148 Screening Cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening P3000 Screening Papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision P3001 Screening Papanicolaou smear, cervical or vaginal, up to three smears, requiring interpretation by physician Q0091 Screening Papanicolaou smear, obtaining, preparing and conveyance of cervical or vaginal smear to laboratory ICD-9 Diagnosis Description: Pap test V72.32 Encounter for Pap cervical smear to confirm findings of recent normal smear following initial abnormal smear V76.2 Special screening for malignant neoplasm, cervix ICD-9-CM Procedure Description: Pap test 91.46 Microscopic examination of specimen from female genital tract, cell block and Pap smear 12/5/2012 Page 5 UB Revenue Description: Pap test 0923 PAP SMEAR LOINC Description: Pap test 10524-7 Pap test 18500-9 Pap test 19762-4 Pap test 19764-0 Pap test 19765-7 Pap test 19766-5 Pap test 19774-9 Pap test 33717-0 Pap test 47527-7 Pap test 47528-5 Pap test Table CCS-B: Codes to Identify Exclusions CPT Procedure Code Description: Hysterectomy 51925 Closure of vesicouterine fistula with hysterectomy 56308 Hysterectomy 58150 Total abdominal hysterectomy, with or without removal of tubes , with or without removal of ovarys 58152 Total abdominal hysterectomy, with colpo-urethrocystopexy 58200 Total abdominal hysterectomy, including partial vaginectomy, with para aortic lymph nodes sampling with or without removal of tubes , with or without removal of ovarys 58210 Radical abdominal hysterectomy, with bilateral total pelvic lymphadenectomy and para aortic lymph node biopsy, with or without removal of tubes , with or without removal of ovarys 58240 Pelvic exenteration for gynecologic malignancy, with total abdominal hysterectomy or cervicectomy, with or without removal of tubes , with or without removal of ovarys, with removal of bladder and ureteral transplantations, and/ or abdominoperinealmresection of rectum and colon and colostomy or any combination 58260 Vaginal hysterectomy for uterus 250 grams or less 58262 Vaginal hysterectomy for uterus 250 grams or less, with removal of tubes, and/ or ovarys 58263 Vaginal hysterectomy for uterus 250 grams or less, with removal of tubes, and/ or ovarys, with repair of enterocele 12/5/2012 Page 6 58267 Vaginal hysterectomy for uterus 250 grams or less, with colpo- urethrocystopexy with or without endoscopic control 58270 Vaginal hysterectomy for uterus 250 grams or less with repair of enterocele 58275 Vaginal hysterectomy, with total or partial vaginectomy 58280 Vaginal hysterectomy with repair of enterocele 58285 Vaginal hysterectomy, radical 58290 Vaginal hysterectomy for uterus greater than 250 grams 58291 Vaginal hysterectomy with removal of tubes and/ or ovarys 58292 Vaginal hysterectomy with removal of tubes and/ or ovarys, with repair of enterocele 58293 Vaginal hysterectomy with
Load more

Recommended publications
  • Gyn Oncology Colposcopy I. Basic Science/Mechanisms of Disease A
    Gyn Oncology Colposcopy I. Basic Science/Mechanisms of Disease A. Genetics 1. Describe the clinical relevance of viral oncogenes. 2. Describe the role of aneuploidy in the pathogenesis of neoplasia. 3. Describe the inheritance patterns for malignancies of the pelvic organs and breast. 4. Describe the cell replication cycle, and identify the phases of the cycle most sensitive to radiation and chemotherapy. 5. Describe the genetic basis for tumor immunotherapy. B. Physiology 1. Describe the ability of vital organ systems to tolerate cancer therapy. 2. Describe the changes in cellular physiology that result from injury due to radiation and chemotherapy. 3. Describe the metabolic changes that occur in patients with a malignancy of the pelvic organs or breast. C. Embroyology 1. Describe the embryology of gonadal migration and its role in the pathogenesis of epithelial cell tumors. 2. Describe the pathogenesis of gonadal tumors in patients with gonadal dysgenesis. 3. Describe the embryologic precursors of ovarian germ cell tumors. D. Anatomy 1. Describe the gross histologic anatomy of the pelvic organs and breast. 2. Describe the vascular, lymphatic, and nerve supply to each of the pelvic organs. 3. Describe the anatomic relationship between the reproductive organs and other viscera, such as bladder, ureters, and bowel. 4. Describe the likely changes in the anatomic relationships of the pelvic and abdominal viscera created by surgical or radiation treatment for malignancy. E. Pharmacology 1. List major chemotherapeutic agents used for treatment of malignancies of the reproductive organs and breast. 2. Describe the principal adverse effects of the major chemotherapeutic agents. 3. Describe the medications of most value in treatment of complications resulting from chemotherapy and irradiation, such as: a.
    [Show full text]
  • Physiology of Female Sexual Function and Dysfunction
    International Journal of Impotence Research (2005) 17, S44–S51 & 2005 Nature Publishing Group All rights reserved 0955-9930/05 $30.00 www.nature.com/ijir Physiology of female sexual function and dysfunction JR Berman1* 1Director Female Urology and Female Sexual Medicine, Rodeo Drive Women’s Health Center, Beverly Hills, California, USA Female sexual dysfunction is age-related, progressive, and highly prevalent, affecting 30–50% of American women. While there are emotional and relational elements to female sexual function and response, female sexual dysfunction can occur secondary to medical problems and have an organic basis. This paper addresses anatomy and physiology of normal female sexual function as well as the pathophysiology of female sexual dysfunction. Although the female sexual response is inherently difficult to evaluate in the clinical setting, a variety of instruments have been developed for assessing subjective measures of sexual arousal and function. Objective measurements used in conjunction with the subjective assessment help diagnose potential physiologic/organic abnormal- ities. Therapeutic options for the treatment of female sexual dysfunction, including hormonal, and pharmacological, are also addressed. International Journal of Impotence Research (2005) 17, S44–S51. doi:10.1038/sj.ijir.3901428 Keywords: female sexual dysfunction; anatomy; physiology; pathophysiology; evaluation; treatment Incidence of female sexual dysfunction updated the definitions and classifications based upon current research and clinical practice.
    [Show full text]
  • AAGL Practice Report: Practice Guidelines for Management of Intrauterine Synechiae
    Special Article AAGL Practice Report: Practice Guidelines for Management of Intrauterine Synechiae AAGL ADVANCING MINIMALLY INVASIVE GYNECOLOGY WORLDWIDE Background The search was not restricted to English language literature; committee members fluent in languages other than English re- Intrauterine adhesions (IUAs) have been recognized as viewed relevant articles and provided the committee with rel- a cause of secondary amenorrhea since the end of the 19th ative information translated into English. Because of the century [1], and in the mid-20th century, Asherman further paucity of data in this area, all published works were included described the eponymous condition occurring after preg- for the electronic database searches, and relevant articles not nancy [2]. The terms ‘‘Asherman syndrome’’ and IUAs are available in electronic sources (e.g., published before the be- often used interchangeably, although the syndrome requires ginning of electronic database commencement) were cross- the constellation of signs and symptoms (in this case, pain, referenced from hand-searched bibliographies and included menstrual disturbance, and subfertility in any combination) in the literature review. When necessary, authors were con- and the presence of IUAs [2]. The presence of IUAs in the tacted directly for clarification of points published. absence of symptoms may be best referred to as asymptom- atic IUAs or synechiae. Diagnosis Identification and Assessment of Evidence In women with suspected IUAs, physical examination usually fails to reveal abnormalities [3,4]. Blind transcervical This AAGL Practice Guideline was produced after elec- sounding of the uterus may reveal cervical obstruction at or tronic resources including Medline, PubMed, CINAHL, the near the level of the internal os [3].
    [Show full text]
  • OBGYN Student Guide 2014.Pdf
    TABLE OF CONTENTS COMMON ABBREVIATIONS • 3 COMMON PRESCRIPTIONS • 4 OBSTETRICS • 5 What is a normal morning like on OB? • 5 What are good questions to ask a post-op/post-partum patient in the morning? • 6 How do I manage a post-partum patient? • 7 How should I organize and write my post-partum note? • 8 How do I present a patient on rounds? • 9 How do I evaluate a patient in triage/L&D? • 9 What are the most common complaints presented at triage/L&D? • 10 How should I organize and write my note for a triage H&P? • 12 What are the most common reasons people are admitted? • 13 How do I deliver a baby? • 13 What is my role as a student in a Cesarean section or tubal ligation procedure? • 15 How do I write up post-op orders? • 15 GYNECOLOGY/GYNECOLOGY ONCOLOGY • 17 What should I do to prepare for a GYN surgery? • 17 How do I manage a Gynecology/Gynecology Oncology patient? • 17 How should I organize and write my post-op GYN note? • 18 How do I write admit orders? • 19 What do routine post-op orders (Day #1) look like? • 19 What are the most common causes of post-operative fever? • 20 CLINIC • 21 What is my role as a student in clinic? • 21 What should I include in my prenatal clinic note? • 21 What should I include in my GYN clinic note? • 22 COMMON PIMP QUESTIONS • 23 2 COMMON ABBREVIATIONS 1°LTCS- primary low transverse cesarean LOF- leakage of fluid section NST- nonstress test AFI- amniotic fluid index NSVD- normal spontaneous vaginal delivery AROM- artificial rupture of membranes NT/NE- non-tender/non-engorged (breast BPP- biophysical
    [Show full text]
  • Comparison of Curettage and Hysteroscopy Plus Curettage After Uterine Arterial Embolization in the Treatment of Cesarean Scar Pregnancy
    Comparison of Curettage and Hysteroscopy Plus Curettage After Uterine Arterial Embolization in the Treatment of Cesarean Scar Pregnancy Lili Cao Women's Hospital, Zhejiang University School of Medicine Zhida Qian Women's Hospital, Zhejiang University School of Medicine Lili Huang ( [email protected] ) Women's Hospital, Zhejiang University School of Medicine https://orcid.org/0000-0002-5919-3172 Research article Keywords: Cesarean scar pregnancy, Hysteroscopy, Curettage, Uterine artery embolization Posted Date: July 2nd, 2020 DOI: https://doi.org/10.21203/rs.3.rs-39244/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/11 Abstract Background: Caesarean scar pregnancy (CSP) stands for the advanced stage severe complication secondary to cesarean section, and its incidence shows an increasing trend recently. However, no consensus has been reached about the optimal CSP treatment. Methods: The childbearing CSP patients with a cesarean section history were evaluated by ultrasonography, with a gestational age of less than 10 weeks. 34 patients receiving dilation and curettage (D&C) and uterine artery embolization (UAE) were enrolled into the D&C group, while 46 undergoing hysteroscopy (H/S) and D&C after UAE were enrolled into the H/S+D&C group. Results: Differences in success rate and decrease in the β-hCG level in serum on the second day of surgery were not signicant between D&C and H/S+D&C groups (P>0.05). Also, differences in side effect rate, intraoperative blood loss amount, postoperative bleeding time, and total length of stay were not signicant between both groups (P>0.05).
    [Show full text]
  • Oophorectomy Or Salpingectomy— Which Makes More Sense?
    Oophorectomy or salpingectomy— which makes more sense? During hysterectomy for benign indications, many surgeons routinely remove the ovaries to prevent cancer. Here’s what we know about this practice. William H. Parker, MD CASE Patient opts for hysterectomy, asks than age 45 to prevent the subsequent devel- about oophorectomy opment of ovarian cancer (FIGURES 1 and 2). Your 46-year-old patient reports increasingly The 2002 Women’s Health Initiative re- severe dysmenorrhea at her annual visit, and a port suggested that exogenous hormone use pelvic examination reveals an enlarged uterus. was associated with a slight increase in the You order pelvic magnetic resonance imaging, risk of breast cancer.2 After its publication, which shows extensive adenomyosis. the rate of oophorectomy at the time of hys- After you counsel the patient about terectomy declined slightly, likely reflect- IN THIS her options, she elects to undergo lapa- ARTICLE ing women’s desire to preserve their own roscopic supracervical hysterectomy and source of estrogen.3 For women younger Algorithm: Should asks whether she should have her ovaries than age 50, further slight declines in the rate the ovaries removed at the time of surgery. She has no of oophorectomy were seen from 2002 to be removed? family history of ovarian or breast cancer. 2010. However, in the United States, almost page 54 What would you recommend for this 300,000 women still undergo “prophylactic” woman, based on her situation and current bilateral salpingo-oophorectomy every year.4 medical research? The lifetime risk of ovarian cancer Ovarian cancer does among women with a BRCA 1 mutation not come from the prophylactic procedure should be is 36% to 46%, and it is 10% to 27% among ovary considered only if 1) there is a rea- women with a BRCA 2 mutation.
    [Show full text]
  • ICD-9-CM Procedure Version 23
    GEM Documentation and Users Guide 2007 version Procedure Code Set General Equivalence Mappings ICD-10-PCS to ICD-9-CM and ICD-9-CM to ICD-10-PCS 2007 Version Documentation and User’s Guide Preface Purpose and Audience This document accompanies the 2007 update of the CMS public domain reference mappings of the ICD-10 Procedure Code System (ICD-10-PCS) and ICD-9-CM Volume 3. The purpose of this document is to give potential users the information they need to understand the structure and relationships contained in the mappings so they can use them correctly. The intended audience includes but is not limited to professionals working in health information, medical research and informatics. General interest readers may find section 1 useful. Those who may benefit from the material in both sections 1 and 2 include clinical and health information professionals who plan to directly use the mappings in their work. Software engineers and IT professionals interested in the details of the file format will find this information in Appendix A. In This Document For readability, ICD-9-CM is abbreviated “I-9,” and ICD-10-PCS is abbreviated “PCS.” The network of relationships between the two code sets described herein is called the General Equivalence Mappings (GEMs). • Section 1 is a general interest discussion of mapping as it pertains to the GEMs. It includes a discussion of the difficulties inherent in linking two coding systems of very different design and structure. The specific conventions and terms employed in the GEMs are discussed in more detail. • Section 2 contains detailed information on how to use the GEM files, for users who will be working hands-on with mapping applications now or in the future—as coding experts, researchers, claims processing personnel, software developers, etc.
    [Show full text]
  • Gender Confirmation Surgery Reference Number: PA.CP.MP.95 Effective Date: 01/18 Coding Implications Last Review Date: 09/17 Revision Log
    Clinical Policy: Gender Confirmation Surgery Reference Number: PA.CP.MP.95 Effective Date: 01/18 Coding Implications Last Review Date: 09/17 Revision Log Description Services for gender confirmation most often include hormone treatment, counseling, psychotherapy, complete hysterectomy, bilateral mastectomy, chest reconstruction or augmentation as appropriate, genital reconstruction, facial hair removal, and certain facial plastic reconstruction. Not every individual will require each intervention so necessity needs to be considered on an individualized basis. This criteria outlines medical necessity criteria for gender confirmation surgery when such services are included under the members’ benefit plan contract provisions. Policy/Criteria It is the policy of Pennsylvania Health and Wellness® (PHW) that the gender confirmation surgeries listed in section III are considered medically necessary for members when diagnosed with gender dysphoria per criteria in section I and when meeting eligibility criteria in section II. I. Gender Dysphoria Criteria, meets A and B A. Marked incongruence between the member’s experienced/expressed gender and assigned gender, of at least 6 month’s duration, as indicated by two or more of the following: 1. Marked incongruence between the member’s experienced/expressed gender and primary and/or secondary sex characteristics; 2. A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender; 3. A strong desire for the primary and/or secondary sex characteristics of the other gender; 4. A strong desire to be of the other gender (or some alternative gender different from one’s assigned gender); 5. A strong desire to be treated as the other gender (or some alternative gender different from one’s assigned gender); 6.
    [Show full text]
  • Once in a Lifetime Procedures Code List 2019 Effective: 11/14/2010
    Policy Name: Once in a Lifetime Procedures Once in a Lifetime Procedures Code List 2019 Effective: 11/14/2010 Family Rhinectomy Code Description 30160 Rhinectomy; total Family Laryngectomy Code Description 31360 Laryngectomy; total, without radical neck dissection 31365 Laryngectomy; total, with radical neck dissection Family Pneumonectomy Code Description 32440 Removal of lung, pneumonectomy; Removal of lung, pneumonectomy; with resection of segment of trachea followed by 32442 broncho-tracheal anastomosis (sleeve pneumonectomy) 32445 Removal of lung, pneumonectomy; extrapleural Family Splenectomy Code Description 38100 Splenectomy; total (separate procedure) Splenectomy; total, en bloc for extensive disease, in conjunction with other procedure (List 38102 in addition to code for primary procedure) Family Glossectomy Code Description Glossectomy; complete or total, with or without tracheostomy, without radical neck 41140 dissection Glossectomy; complete or total, with or without tracheostomy, with unilateral radical neck 41145 dissection Family Uvulectomy Code Description 42140 Uvulectomy, excision of uvula Family Gastrectomy Code Description 43620 Gastrectomy, total; with esophagoenterostomy 43621 Gastrectomy, total; with Roux-en-Y reconstruction 43622 Gastrectomy, total; with formation of intestinal pouch, any type Family Colectomy Code Description 44150 Colectomy, total, abdominal, without proctectomy; with ileostomy or ileoproctostomy 44151 Colectomy, total, abdominal, without proctectomy; with continent ileostomy 44155 Colectomy,
    [Show full text]
  • Hysterectomy with Bilateral Salpingo- Oophorectomy
    Hysterectomy with Bilateral Salpingo- Oophorectomy Hysterectomy is a surgical procedure to remove all or part of the uterus*, and sometimes the ovaries* and/or fallopian tubes*; a gender-affirming, masculinizing lower surgery. Oophorectomy is a surgery to remove the ovaries*; a gender-affirming, masculinizing lower surgery. How is a hysterectomy with bilateral salpingo oophorectomy performed? 1. 3 to 5 tiny incisions are made on your abdomen. 2. Gas is put into your abdomen to inflate it. 3. A very small telescope is inserted in one of the incisions so the surgeon can see inside. 4. Long, narrow instruments are inserted through the incisions to detach the uterus*, fallopian tubes*, ovaries*, and cervix*. 5. These tissues are removed through the vagina*. 6. The top of the vagina* is closed with stitches that will dissolve over time. 7. The gas is released. Will I need to stay in the hospital? You will likely be discharged the same day as the surgery What medications will I be prescribed after surgery? You will likely receive painkillers and antibiotics to reduce the chance of infection. What should I expect after my procedure? • Discomfort in your belly • Pain in your upper chest and shoulder area, due to the gas used to inflate your abdomen. • Pink, brown or yellowish brown discharge from vagina* for 4 to 6 weeks • You may pass some stitches and this is normal • Incisions may be red with some bruising. This will slowly go away. • Incisions will be closed with steri-strips, sutures or staples. Your surgeon will let you know whether and how these will be removed.
    [Show full text]
  • (8Th Edition) Procedure Code ACHI (8
    Appendix 1. Procedure and Diagnostic Codes Used to Identify Prior Procedures Procedure ACHI (8th ACHI (8th edition) procedure names ICD-10- ICD-10-AM edition) AM diagnosis name procedure diagnosis code code Gynecological laparoscopy 35638-00 Laparoscopic wedge resection of ovary 35638-01 Laparoscopic partial oophorectomy 35638-02 Laparoscopic oophorectomy, unilateral 35638-03 Laparoscopic oophorectomy,bilateral 35638-04 Laparoscopic ovarian cystectomy, unilateral 35638-05 Laparoscopic ovarian cystectomy, bilateral 35638-06 Laparoscopic salpingotomy 35638-07 Laparoscopic partial salpingectomy, unilateral 35638-08 Laparoscopic partial salpingectomy, bilateral 35638-09 Laparoscopic salpingectomy, unilateral 35638-10 Laparoscopic salpingectomy, bilateral 35638-11 Laparoscopic salpingo-oophorectomy, unilateral 35638-12 Laparoscopic salpingo-oophorectomy, bilateral 35638-14 Laparoscopic uterosacral nerve ablation 35637-02 Laparoscopic diathermy of lesion of pelvic cavity 35637-04 Laparoscopic ventrosuspension 35637-07 Laparoscopic rupture of ovarian cyst or abscess 35637-08 Laparoscopic ovarian drilling 35637-10 Laparoscopic excision of lesion of pelvic cavity 35729-00 Laparoscopic transposition of ovary 90430-00 Laparoscopic repair of ovary 90433-00 Other laparoscopic repair of fallopian tube 35694-00 Laparoscopic salpingoplasty 35694-01 Laparoscopic anastomosis of fallopian tube 35694-02 Laparoscopic salpingolysis 35694-03 Laparoscopic salpingostomy 35694-06 Laparoscopic salpingotomy 35649-01* Myomectomy of uterus via laparoscopy Hysteroscopy, including operative hysteroscopy 35630-00 Diagnostic hysteroscopy 35649-00 Hysterotomy 35633-00 Division of uterine adhesions 35634-00 Division of uterine septum via hysteroscopy 35649-02 Division of uterine septum via hysterotomy 35633-01 Polypectomy of uterus via hysteroscopy 35623-00 Myomectomy of uterus via hysteroscopy Baldwin HJ, Patterson JA, Nippita TA, Torvaldsen S, Ibiebele I, Simpson JM, et al. Antecedents of abnormally invasive placenta in primiparous women: the risk from gynecologic procedures.
    [Show full text]
  • Editorial Robert L
    Editorial Robert L. Barbieri, MD Editor in Chief A stitch in time: The B-Lynch, Hayman, and Pereira uterine compression sutures All three of these uterine compression sutures are effective at treating postpartum hemorrhage caused by uterine atony—remember to use them CASE You are performing a cesarean carboprost tromethamine (Hemabate), others. Every obstetrician should be delivery for a 30-year-old G1P0 woman and methergine do not result in resolu- proficient with the placement of at who presented in labor with a breech tion of the hemorrhage. Your assistant least one uterine compression suture fetus at term. Earlier in the pregnancy suggests a uterine compression suture for the treatment of PPH caused by an external version was unsuccessful to treat the PPH. uterine atony. in achieving a cephalic presentation. What uterine compression suture The breech delivery of the newborn would you choose? Consider the hysterotomy is uncomplicated but, immediately When it’s open. When PPH caused following delivery of the placenta, he management of PPH can by uterine atony occurs at cesarean you note excessive uterine bleeding be conveniently described delivery and the hysterotomy inci- and diagnose a postpartum hemor- T using one algorithm for cases sion is open, the B-Lynch suture rhage (PPH) due to uterine atony. that follow a vaginal delivery, and ( FIGURE 1, page 8) is a common se- Manual massage of the uterus and another algorithm for PPH that lection by obstetricians. administration of oxytocin, misoprostol, occurs during cesarean delivery (see When it’s closed. When the hys- “Managing PPH following vaginal terotomy is already closed when and cesarean delivery” on page 10).
    [Show full text]